Skip to content
DataLookout
Menu

LEADNCT04403165

Locus-coeruleus Function in Normal Elderly and AD Risk

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 8 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 6, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Primary endpoints: 8 to 10
    • Enrollment target: 30 to 34
    • Secondary endpoint revised
  2. Notable Primary endpoints revised (8)v9
  3. Notable Eligibility criteria shortened, about 68 wordsv7
  4. Minor Trial status: Recruiting to Completed
    • Primary and study completion dates changed from estimate of Aug 31, 2024 to Mar 26, 2024
    • Site details revised at 2 of 2 sites
    v6
  5. Notable Primary and study completion dates: Aug 2023 to Aug 31, 2024v5
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Primary and study completion dates: Aug 2022 to Aug 2023v4
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
    • Primary and study completion dates moved earlier to Aug 2022
    • Eligibility criteria expanded, about 58 words
    • Primary endpoints: 4 to 8
    • Study sites: 0 to 2
    • Start date changed from estimate of Jul 2021 to Aug 6, 2020
    • Interventions: Lumbar Puncture (LP) (Procedure), MRB PET-MR scan (Procedure), nocturnal polysomnography (NPSG) (Other) to Lumbar Puncture (LP) (Procedure), Nocturnal polysomnography (NPSG) (Procedure), PET-MR measurement with a norepinephrine transporter…
    • Secondary endpoints expanded, about 6 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Timeframe: Visit 4 (1-4 weeks after LP that occurred on day 14)
Total Rapid Eye Movement (REM) Duration (Min)
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Time Spent in REM Sleep
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Less Than 5 Minutes
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Correct Responses on the Picture Test
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Picture Test Response Time
Timeframe: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

Secondary (1)

Levels of Hyperphosphorylated Tau (P-Tau)

Arms and interventions

Cognitively Normal (CN) Older AdultsExperimental

Procedures: Nocturnal polysomnography (NPSG), Lumbar Puncture (LP)

Other: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)

Behavioral: Psychomotor Vigilance Task (PVT)

Sites

2 sites in 1 country